USOR 25137 - Ph3 of LY4170156 vs Chemo or Mirvetuximab Soravtansine in Ovarian (FRAmework-01)

A Three-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) versus Chemotherapy or Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer, and Sofetabart Mipitecan plus Bevacizumab versus Platinum-Based Chemotherapy plus Bevacizumab in Platinum-Sensitive Ovarian Cancer

Disease Types: Gynecological/Ovarian

Available at: Arlington Heights, Chicago, Niles